 |
 |
 |
Journal articles
US Food and Drug Administration approval of esketamine and brexanolone
Abstract : In March 2019, The USFood and Drug Administration (FDA) approved twonew antidepressants -esketamine for treatment-resistant depression (TRD)1and brexanolone for postpartum depression (PPD).
Cited literature [13 references]
https://hal-univ-rennes1.archives-ouvertes.fr/hal-02363651
Contributor : Laurent Jonchère Connect in order to contact the contributor
Submitted on : Tuesday, February 18, 2020 - 10:32:49 AM
Last modification on : Wednesday, November 3, 2021 - 8:47:53 AM
Long-term archiving on: : Tuesday, May 19, 2020 - 1:20:47 PM
Contributor : Laurent Jonchère Connect in order to contact the contributor
Submitted on : Tuesday, February 18, 2020 - 10:32:49 AM
Last modification on : Wednesday, November 3, 2021 - 8:47:53 AM
Long-term archiving on: : Tuesday, May 19, 2020 - 1:20:47 PM
File
Cristea_et al_2019_US FDA appr...
Files produced by the author(s)